Product Information
RELISTOR 8 MG/0.4 ML SYRINGE is a brand product labeled by Salix Pharmaceuticals Inc., priced at $409.7653 per ML under NDC 65649055204. Its NADAC has been published 220 times since Nov 19, 2014.
FDA first approved this application on Apr 24, 2008.
Strength
8 mg/.4mL
Manufacturer
Salix Pharmaceuticals Inc.NDC
65649055204
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
1/1/2025
Active Ingredients
METHYLNALTREXONE BROMIDEApproval Type
New Drug (NDA)
FDA Application
NDA021964FDA Approved
4/24/2008
On Market Since
4/24/2008
Pharmacological Classes
Price Statistics
The NADAC for RELISTOR 8 MG/0.4 ML SYRINGE has been published 220 times since Nov 19, 2014, and over the history we have for it it has risen 158.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $409.7653 per ML |
|---|---|
| All-time high | $409.7653 (Oct 1, 2025) |
| All-time low | $158.3893 (Nov 19, 2014) |
| Median price | $264.8895 |
| Average price | $284.3613 |
| Largest weekly change | +45.7% (May 22, 2024) |
| Weeks tracked | 220 |
| Tracking since | Nov 19, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+54.7%
5Y
+54.7%
All
+158.7%
Last surveyed Oct 1, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Methylnaltrexone bromide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Salix Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylnaltrexone bromide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RELISTOR 8 MG/0.4 ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for RELISTOR 8 MG/0.4 ML SYRINGE, manufactured by Salix Pharmaceuticals Inc., is $409.7653 per ML (NDC 65649055204), effective Oct 1, 2025.
How has the price of RELISTOR 8 MG/0.4 ML SYRINGE changed over time?
Over the history we have for it, the NADAC for RELISTOR 8 MG/0.4 ML SYRINGE has risen 158.7%. It has been tracked across 220 weekly CMS publications since Nov 19, 2014.
What are the highest and lowest recorded NADAC prices for RELISTOR 8 MG/0.4 ML SYRINGE?
Since Nov 19, 2014, the NADAC for RELISTOR 8 MG/0.4 ML SYRINGE has ranged from a low of $158.3893 (Nov 19, 2014) to a high of $409.7653 (Oct 1, 2025), with a median of $264.8895 per ML.
Are there cheaper alternatives to RELISTOR 8 MG/0.4 ML SYRINGE?
No other NADAC-published product currently shares the active ingredient and strength of RELISTOR 8 MG/0.4 ML SYRINGE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RELISTOR 8 MG/0.4 ML SYRINGE?
RELISTOR 8 MG/0.4 ML SYRINGE (NDC 65649055204) is labeled by Salix Pharmaceuticals Inc., and CMS classifies it as a brand product.